MedTrace Logo

EndoTic - Endothelium and Ticagrelor

NCT02244710 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 109

Last updated 2016-11-23

No results posted yet for this study

Summary

Randomized clinical trial to assess the influence of treatment with ticagrelor or clopidogrel in the number of CECs (Circulating Endothelial Cells) and EPCs (Endothelial Progenitor Cells) in patients with ACS (Acute Coronary Syndrome), from baseline levels to chronic levels (1 month).

Conditions

  • Acute Coronary Syndrome (ACS)

Interventions

DRUG

Ticagrelor vs Clopidogrel

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Fundación Investigación Sanitaria en León

    lead OTHER

Principal Investigators

  • Armando Pérez de Prado, MD, PhD · Fundación Investigación Sanitaria en León

  • M. Belen Vidriales Acosta, MD, PhD · University of Salamanca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2016-09-30
Completion
2016-09-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02244710 on ClinicalTrials.gov